1. Home
  2. PRLD vs AGD Comparison

PRLD vs AGD Comparison

Compare PRLD & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$3.84

Market Cap

391.1M

Sector

Health Care

ML Signal

HOLD

Logo abrdn Global Dynamic Dividend Fund of Beneficial Interest

AGD

abrdn Global Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$12.04

Market Cap

329.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRLD
AGD
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
391.1M
329.6M
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
PRLD
AGD
Price
$3.84
$12.04
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$5.67
N/A
AVG Volume (30 Days)
484.2K
125.2K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
23.21
N/A
EPS
N/A
N/A
Revenue
$12,140,000.00
N/A
Revenue This Year
$320.10
N/A
Revenue Next Year
$100.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
73.43
N/A
52 Week Low
$0.75
$10.41
52 Week High
$5.69
$13.98

Technical Indicators

Market Signals
Indicator
PRLD
AGD
Relative Strength Index (RSI) 35.95 46.65
Support Level $3.40 $11.84
Resistance Level $4.13 $12.31
Average True Range (ATR) 0.32 0.15
MACD -0.11 0.00
Stochastic Oscillator 3.85 48.75

Price Performance

Historical Comparison
PRLD
AGD

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest

Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.

Share on Social Networks: